NCT04661111View on ClinicalTrials.gov

Efficacy and Safety of Hymovis ONE® (32mg/4ml) Intrarticular Injection in Active Patients With Knee Overuse Syndrome

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

September 28, 2017

Study Completion Date

June 28, 2018

Conditions
Knee Osteoarthritis
Interventions
DEVICE

Hymovis® ONE (32 mg/4 ml)

Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.

Trial Locations (1)

00161

"Università di Roma La Sapienza, Azienda Policlinico Umberto I, Roma", Roma

Sponsors
All Listed Sponsors
lead

Fidia Farmaceutici s.p.a.

INDUSTRY